<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001091</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-034</org_study_id>
    <nct_id>NCT01001091</nct_id>
  </id_info>
  <brief_title>AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ophthalmic Research Associates, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment
      of the signs of inflammation associated with allergic conjunctivitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean area under the curve 0-7 hours post-CAC for conjunctival redness scores</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean daily diary ocular redness scores</measure>
    <time_frame>2 week period between Day 0 and Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>AL-38583 0.01%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-38583 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-38583 0.2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-38583 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAXIDEX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-38583 ophthalmic solution</intervention_name>
    <arm_group_label>AL-38583 0.01%</arm_group_label>
    <arm_group_label>AL-38583 0.05%</arm_group_label>
    <arm_group_label>AL-38583 0.2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-38583 ophthalmic solution vehicle</intervention_name>
    <description>Inactive ingredients used as a placebo comparator</description>
    <arm_group_label>AL-38583 Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone ophthalmic suspension, 0.1%</intervention_name>
    <arm_group_label>MAXIDEX</arm_group_label>
    <other_name>MAXIDEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of signs and symptoms of ocular inflammation in both eyes.

          -  Have a positive CAC response at Visit 1.

          -  Able to avoid the use of disallowed medications as well as contact lens wear for the
             specified period prior to Visit 1, and for the duration of the study.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Have known history or presence of persistent dry eye syndrome.

          -  Presence of any ophthalmic abnormality that may affect the study outcomes.

          -  Have a history of moderate to severe allergic asthma reaction to mountain cedar or the
             perennial allergens used in the study.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michela Palmer</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2009</study_first_submitted>
  <study_first_submitted_qc>October 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2009</study_first_posted>
  <disposition_first_submitted>July 15, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 15, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 17, 2014</disposition_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjunctivitis</keyword>
  <keyword>conjunctival inflammation</keyword>
  <keyword>ocular allergies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

